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vitro. Co-expression of Dlx2 activated p107-luciferase promoter gene expression in vitro.
p107 expression was reduced in the Dlx1/Dlx2 DKO mouse retina at E18.5. DLX2 was
expressed in the nuclei of Chx10:Rb-p107 conditional DKO retinoblastoma as well as in
almost all human retinoblastoma tissues we studied.
Conclusions: The homeodomain transcription factor DLX2 directly activates expression of
the tumour suppressor p107, a member of the Rb pocket protein family essential for cell cycle
regulation. Expression of DLX2 in both mouse and human retinoblastoma supports that these
developmental tumours are partially differentiated and contributes to our knowledge
regarding the cell of origin. Future studies will determine whether modulation of DLX2
expression regulates cell proliferation and differentiation of retinoblastoma.
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Objectives: Canadian Guidelines for Retinoblastoma Care1 recommend testing infants
for their affected parent’s RB1 mutation prenatally or at birth; infants carrying the RB1
mutation may be delivered late pre-term [HD1] or near-term (36, 37 weeks gestation) to
optimize opportunities for minimal impact treatment of small tumors. We evaluate effects
of gestational age at first eye examination on outcomes of children carrying an RB1
mutation.
Methods: We retrospectively studied infants carrying their family’s RB1 mutation, born
between 1 June 1996 and 31 May 2013 and treated at SickKids. Information collected
included: affected parent; sex; gestational age at birth, RB1 testing and first eye exam;
pregnancy or perinatal complications; type of sample tested and RB1 mutation; locations of
first and subsequent tumors; International Intraocular Retinoblastoma Classification and
Tumour Node Metastasis staging; treatments delivered; last followup date; and overall and
visual outcomes.
Results: Twenty infants carried their parent’s RB1 mutation, detected prenatally in 12 and
after birth in 8. Nine were tested prenatally and electively delivered at 36-37 weeks gestation
and 3 were spontaneously premature. All infants not tested prenatally were born at term. All
newborn infants had weekly eye examinations. Vision-threatening tumors were present at
birth in 25% (3/12) of infants delivered early or born prematurely and 75% (6/8) of full-term
infants; posterior tumors appeared age 1 to 6 months in 9 infants. All patients eventually
developed bilateral retinoblastoma. Good vision was maintained in all children born early;
treatments included focal therapy (all) and later chemotherapy (5), stereotactic radiation and
enucleation of one eye due to chemotherapy intolerance (1). Full-term infants received focal
therapy (8), chemotherapy (5), and enucleation of one eye (2); bilateral macular tumors
blinded one child.
Conclusion
Prenatal molecular detection and early delivery facilitated optimal outcomes.
1. National Retinoblastoma Strategy Canadian Guidelines for Care. Canadian Journal of
Ophthalmology. 2009;44:S1-88.
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Objectives: To evaluate efficacy of systemic chemo-reduction using topotecan for advanced
intraocular retinoblastoma.
Methods: 27 newly diagnosed bilateral retinoblastoma patients (14 males, median age 7.9
months), worse eye Reese- Ellsworth (RE) group IV-V, received 11 cycles of chemotherapy:
topotecan and vincristine (TV) x 2 followed by three alternating courses of carboplatin and
vincristine x 2 and TV x 1. Intensive focal therapy was applied after the first 2 cycles. Event
free survival (EFS) was defined as avoidance of external beam radiation (EBRT) and
enucleation.
Results: Of 54 eyes, 42 were RE IV-Vand 37 were International Classification (IC) C-E. 24
patients (89%) completed all prescribed chemotherapy; one was removed due to persistent
viral infection and two had progressive disease requiring EBRT. All eyes received focal
therapy. Seven patients received subconjunctival carboplatin during therapy, and six received
plaque brachytherapy during follow-up. Eleven eyes were enucleated: one at diagnosis, nine
with progressive disease including three eyes treated with EBRT, and one which developed
neovascular glaucoma. At 8 years, cumulative incidence of EBRT was 2.4% (SE! 2.4) and
EFS for patients was 66.7% (SE! 38.5). Ocular survival for RE group IV-Veyes was 76.2%
(SE! 26.3) and 70% (SEþ 27.0) for IC group D-E eyes. All patients experienced
thrombocytopenia (41 episodes in 275 courses, 15%). There were 29 episodes of febrile
neutropenia (10%). Fifteen patients had a documented source of infection (40% viral
etiology). Grade 3 diarrheawas present in 9/27 patients, and one patient reacted to carboplatin.
All patients are alive with median follow up was 7.4 years.
Conclusions: Topotecan combined with vincristine, carboplatin and aggressive focal
therapies is an effective regimen for the treatment of advanced retinoblastoma (RE IV-V) that
avoids radiation and results in globe salvage with measurable vision. Toxicities were
anticipated and managed with appropriate supportive care.
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Objectives: To determine the effectiveness and safety of injections of Melphalan via the
ophthalmic artery (SOAC), or into the vitreous cavity (IVC), or of periocular Topotecan
(POT), as salvage therapies for recurrent/progressive retinoblastoma (Rb) according to the site
of recurrence/progression. To evaluate the eye preservation rate after 3 courses of SOAC, 3
courses of IVC, 2 courses of POT (no enucleation and/or radiotherapy).
Methods: National single arm phase II prospective study including patients (pts) with
recurrent/progressive Rb between 6 months and 15 years of age after failure to prior
treatment (chemoreduction/focal therapy, plaque therapy, external beam radiation), with
RetCam images and ultrasound biomicroscopy for identification of tumor-free meridian
mandatory for IVC. Each patient was enrolled and evaluated only for one treatment arm.
Response was evaluated after each treatment course for retinal tumors and/or vitreous
seeds. Treatment was stopped at any time in case of progression, toxicity or parental
refusal.
Results: Thirty-one pts were registered, 14 (4 with unilateral and 10 with bilateral disease)
were eligible after failure to prior chemotherapy only (12) or chemotherapy/radiotherapy (2).
Salvage treatment consisted of SOAC in 7, IVC in 5 and POT in 2 pts. Responsewas favorable
in 3/7 SOAC, 5/5 IVC and 2/2 POTadministrations. Therewas no enucleation or radiotherapy
after a median follow-up of 7 months (1-16). Six out of 14 pts needed further treatment, 5 in
the same eye (SOAC 1, IVC 1, combined SOAC/IVC 3), 1 in the contralateral eye (combined).
Ocular hemorrhage in 2/14 eyes after SOAC was the worst adverse event observed, treated
successfully with anti-VEGF.
Conclusions: In heavily pretreated Rb patients SOAC, IVC and POT are efficient in treating
recurrent/progressive disease and preventing enucleation and/or radiotherapy. However,
almost half of the treated eyes need further treatment for disease control. Treatment
combinations should be considered in future.
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Objectives: Melphalan-based ophthalmic artery chemosurgery (OAC) has been highly
effective for intra-ocular retinoblastoma, but some patients who achieve remission develop
recurrence following completion of therapy. We aimed to evaluate the efficacy of second
course OAC for such patients.
Methods: Single-arm, retrospective study of 32 eyes that underwent OAC at our centers
between May 2006 and July 2013 and achieved remission, but suffered intra-ocular
retinoblastoma recurrence at least 2 months off-therapy. Outcome measurements included
Kaplan-Meier estimates of ocular progression-free survival (PFS) and ocular survival, and the
Mantel-Cox test was used to compare curves.
Results:The eyes previously received amean of 3.1 first course OAC infusions and developed
off-therapy disease recurrence at a median of 4.4months following completion of initial OAC.
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